Table 2.
|
Response mBev |
|||
---|---|---|---|---|
Activity BT |
CR |
PR |
SD |
PD |
n | n(%) | n(%) | n(%) | n(%) |
4 CR |
4 (100) |
|
|
|
18 PR |
|
12 (66.7) |
|
6 (33.3) |
13 SD | 1 (7.7) | 10 (76.9) | 2 (15.4) |
mBev, maintenance Bevacizumab; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease.